These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 11907807)

  • 61. Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status.
    Barresi V; Buttarelli FR; Vitarelli EE; Arcella A; Antonelli M; Giangaspero F
    Hum Pathol; 2009 Dec; 40(12):1738-46. PubMed ID: 19716156
    [TBL] [Abstract][Full Text] [Related]  

  • 62. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas.
    Castro GN; Cayado-Gutiérrez N; Moncalero VL; Lima P; De Angelis RL; Chávez V; Cuello-Carrión FD; Ciocca DR
    Cell Stress Chaperones; 2012 Nov; 17(6):779-90. PubMed ID: 22806482
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
    Marko NF; Prayson RA; Barnett GH; Weil RJ
    Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preferential loss of paternal 19q, but not 1p, alleles in oligodendrogliomas.
    Sanson M; Leuraud P; Marie Y; Delattre JY; Hoang-Xuan K
    Ann Neurol; 2002 Jul; 52(1):105-7. PubMed ID: 12112056
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling.
    Tews B; Felsberg J; Hartmann C; Kunitz A; Hahn M; Toedt G; Neben K; Hummerich L; von Deimling A; Reifenberger G; Lichter P
    Int J Cancer; 2006 Aug; 119(4):792-800. PubMed ID: 16550607
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Oligodendrogliomas: their morphological characteristics and molecular alterations].
    Carrato-Monino C; Ariza A
    Rev Neurol; 2007 Mar 16-31; 44(6):353-9. PubMed ID: 17385172
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
    McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
    Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
    Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M
    Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
    Levin N; Lavon I; Zelikovitsh B; Fuchs D; Bokstein F; Fellig Y; Siegal T
    Cancer; 2006 Apr; 106(8):1759-65. PubMed ID: 16541434
    [TBL] [Abstract][Full Text] [Related]  

  • 71. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; El Hallani S; Sanson M; Crinière E; Rodero M; Carpentier C; Paris S; Laigle-Donadey F; Ducray F; Hoang-Xuan K; Delattre JY
    Cancer Genet Cytogenet; 2007 Sep; 177(2):103-7. PubMed ID: 17854663
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
    Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
    Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
    Ohgaki H; Kleihues P
    J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
    Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
    Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q.
    von Deimling A; Bender B; Jahnke R; Waha A; Kraus J; Albrecht S; Wellenreuther R; Fassbender F; Nagel J; Menon AG
    Cancer Res; 1994 Mar; 54(6):1397-401. PubMed ID: 8137236
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms.
    Singh VY; Chacko G; Chacko AG; Rajshekhar V
    Neurol India; 2014; 62(1):32-6. PubMed ID: 24608451
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status.
    Fathi AR; Vassella E; Arnold M; Curschmann J; Reinert M; Vajtai I; Weis J; Deiana G; Mariani L
    Strahlenther Onkol; 2007 Sep; 183(9):517-22. PubMed ID: 17762927
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular pathology and clinical characteristics of oligodendroglial neoplasms.
    Walker C; du Plessis DG; Joyce KA; Fildes D; Gee A; Haylock B; Husband D; Smith T; Broome J; Warnke PC
    Ann Neurol; 2005 Jun; 57(6):855-65. PubMed ID: 15929038
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
    Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
    Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
    [No Abstract]   [Full Text] [Related]  

  • 80. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
    Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
    Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.